Showing results (1-10 of 352) with videos related to
Sort By:
Pageof 36
Journal of Medicinal Chemistry|July 31, 2013
Toward drugs for protease-activated receptor 2 (PAR2)Mei-Kwan Yau, Ligong Liu, David P FairlieExpert Opinion on Therapeutic Patents|March 4, 2016
Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015)Mei-Kwan Yau, Junxian Lim, Ligong Liu, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 22, 2013
Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonismJunxian Lim, Abishek Iyer, Ligong Liu, et al.Journal of Chemical Information and Modeling|October 8, 2015
Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2Weijun Xu, Junxian Lim, Chai-Yeen Goh, et al.ACS Chemical Biology|February 8, 2017
Biased Signaling by Agonists of Protease Activated Receptor 2Yuhong Jiang, Mei-Kwan Yau, W Mei Kok, et al.Journal of the American Chemical Society|August 8, 2014
Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amidesRobert C Reid, Mei-Kwan Yau, Ranee Singh, et al.Bioorganic & Medicinal Chemistry Letters|January 4, 2016
Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activityMei-Kwan Yau, Ligong Liu, Junxian Lim, et al.ACS Medicinal Chemistry Letters|January 29, 2016
Potent Small Agonists of Protease Activated Receptor 2Mei-Kwan Yau, Jacky Y Suen, Weijun Xu, et al.Accounts of Chemical Research|August 20, 2021
Chemical Modulators of Mucosal Associated Invariant T CellsJeffrey Y W Mak, Ligong Liu, David P FairlieCurrent Medicinal Chemistry|July 2, 2021
Targeting Class IIa HDACs: Insights from Phenotypes and InhibitorsLigong Liu, Lilong Dong, Erika Bourguet, et al.Pageof 36